医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging Obtains Regulatory Authorization to Sell Its Products in Japan

2013年10月24日 AM02:55
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Paris:EOSI)(NYSE Euronext, FR0011191766-EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced that Japanese regulatory authorities have authorized the sale of EOS® and sterEOS®. EOS imaging’s medical imaging system, which is comprised of EOS® and sterEOS®, offers very low radiation dose 2D and 3D X-ray imaging of the full body in a natural weight-bearing position (standing or sitting). It has already been approved for sale in more than 30 countries.

The Company made its first forays into the Japanese market this year with the signing of a distribution agreement. Japan accounts for 17% of the global medical imaging market, making it the world’s second-largest market after the United States.

Marie Meynadier, CEO of EOS imaging, comments: “We are delighted to have obtained authorization to deploy our technology in Japan, which marks a key step in our commercial development in the Asia-Pacific region. In the run-up to obtaining this authorization, we worked for a number of months alongside our local distributor to raise awareness about the benefits of EOS among opinion leaders, who have expressed a great deal of interest in our technology. This positive feedback from the Japanese market supports our development strategy in this country.”

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 70 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group posted 2012 consolidated revenue of €9.42 million and employs 70 people including an R&D team of 25 engineers. The Group is based in Paris and holds three subsidiaries in Cambridge (Massachusetts), in Canada at Montreal and in Germany, and offices in Singapore.

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: Annual results 2013 on January 22, 2014 (after market).

CONTACT

EOS imaging
Anne Renevot, +33 (0)1-5525-6124
CFO
investors@eos-imaging.com
or
NewCap.
Sophie
Boulila / Pierre Laurent, +33 (0)1-4471-9491
Financial
communication and investor relations
eosimaging@newcap.fr
or
The
Ruth Group (US)

Melanie Sollid-Penton, 646-536-7023
Press
relations
msollid@theruthgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表